T-cell immunotherapies
FDA Mandates Enhanced Safety Warnings for CAR-T Therapies Due to Secondary Cancer Risks
CAR-T therapy, secondary cancers, FDA boxed warnings, T-cell malignancies, BCMA-directed, CD19-directed, autologous CAR T-cell immunotherapies.